B细胞淋巴瘤2抑制剂在髓系肿瘤治疗中的机制研究及应用进展

摘要/Abstract

中图分类号:

R733.3

常宇宸, 宋陆茜. B细胞淋巴瘤2抑制剂在髓系肿瘤治疗中的机制研究及应用进展[J]. 内科理论与实践, 2021, 16(04): 272-275.

图/表1

参考文献20

[1]	Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis[J]. Mol Cell, 2001, 8(3): 705-711. pmid:11583631
[2]	Bhola PD, Letai A. Mitochondria-judges and executioners of cell death sentences[J]. Mol Cell, 2016, 61(5): 695-704. doi:10.1016/j.molcel.2016.02.019 URL
[3]	Certo M, Del Gaizo Moore V, Nishimo M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members[J]. Cancer Cell, 2006, 9(5): 351-365. doi:10.1016/j.ccr.2006.03.027 URL
[4]	Letai A, Sorcinelli MD, Beard C, et al. Antiapoptotic BCL-2 is required for maintenance of a model leukemia[J]. Cancer Cell, 2004, 6(3): 241-249. doi:10.1016/j.ccr.2004.07.011 URL
[5]	Reed JC. A day in the life of the Bcl-2 protein: does the turnover rate of Bcl-2 serve as a biological clock for cellular lifespan regulation?[J]. Leuk Res, 1996, 20(2): 109-111. doi:10.1016/0145-2126(95)00135-2 URL
[6]	Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia[J]. Blood, 2003, 101(2): 425-432. doi:10.1182/blood-2002-06-1899pmid:12393493
[7]	Fesik SW. Insights into programmed cell death through structural biology[J]. Cell, 2000, 103(2): 273-282. pmid:11057900
[8]	Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors[J]. Cell Death Differ, 2009, 16(7): 1030-1039. doi:10.1038/cdd.2009.48pmid:19390557
[9]	Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours[J]. Nature, 2005, 435(7042): 677-681. doi:10.1038/nature03579 URL
[10]	Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase Ⅰ study of navitoclax in patients with relapsed or refractory disease[J]. J Clin Oncol, 2012, 30(5): 488-496. doi:10.1200/JCO.2011.34.7898pmid:22184378
[11]	Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia[J]. Cancer Discov, 2014, 4(3): 362-375. doi:10.1158/2159-8290.CD-13-0609 URL
[12]	Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and Biological Correlates of Response in a Phase Ⅱ Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia[J]. Cancer Discov, 2016, 6(10): 1106-1117. pmid:27520294
[13]	Tsao T, Shi Y, Kornblau S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells[J]. Ann Hematol, 2012, 91(12): 1861-1870. doi:10.1007/s00277-012-1537-8 URL
[14]	Teh TC, Nguyen NY, Moujalled DM, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1[J]. Leukemia, 2018, 32(2): 303-312. doi:10.1038/leu.2017.243pmid:28751770
[15]	Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia[J]. Nat Med, 2018, 24(12): 1859-1866. doi:10.1038/s41591-018-0233-1pmid:30420752
[16]	DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study[J]. Lancet Oncol, 2018, 19(2): 216-228. doi:10.1016/S1470-2045(18)30010-X URL
[17]	Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidinevsconventional care regimens in older patients with newly diagnosed AML with >30% blasts[J]. Blood, 2015, 126(3): 291-299. doi:10.1182/blood-2015-01-621664pmid:25987659
[18]	Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-Dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ⅰb/Ⅱ study[J]. J Clin Oncol, 2019, 37(15): 1277-1284. doi:10.1200/JCO.18.01600 URL
[19]	DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J]. Engl J Med, 2020, 383(7): 617-629. doi:10.1056/NEJMoa2012971 URL
[20]	Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial[J]. Blood, 2020, 135(24): 2137-2145. doi:10.1182/blood.2020004856 URL

B细胞淋巴瘤2抑制剂在髓系肿瘤治疗中的机制研究及应用进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表1

参考文献20

相关文章15

编辑推荐

Metrics

本文评价

[1]	王杰强综述, 马德奎审校.Trop2基因与三阴性乳腺癌的研究进展[J]. 外科理论与实践, 2022, 27(05): 473-477.
[2]	李佳, 吕良敬.靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[3]	黄乃思, 陈嘉莹, 嵇庆海, 王宇.靶向药物时代局部晚期甲状腺癌的新辅助治疗[J]. 外科理论与实践, 2021, 26(6): 493-496.
[4]	冯秀娟, 吴涛, 白海.急性髓系白血病DNA异常甲基化及治疗进展[J]. 内科理论与实践, 2021, 16(04): 282-286.
[5]	朱莹莹, 张姣姣, 孙俊楠, 王海嵘.氯喹对脂多糖诱导的Ⅱ型肺泡细胞损伤的影响[J]. 内科理论与实践, 2021, 16(03): 197-201.
[6]	刘泓源, 杨希, 顾豪, 胡丽, 孙怡, 陈辉, 林晓曦.1例复杂静脉畸形的靶向治疗[J]. 组织工程与重建外科杂志, 2020, 16(3): 198-200.
[7]	刘泓源, 葛同鑫, 林晓曦.静脉/淋巴管畸形靶向治疗的研究进展[J]. 组织工程与重建外科杂志, 2020, 16(3): 204-209.
[8]	钱梨寒, 沈柏用.局部进展期胰腺癌综合治疗的研究进展[J]. 外科理论与实践, 2020, 25(05): 442-446.
[9]	宋阿会，佟琰，刘英莉.BK通道抑制剂对人脐带华通胶来源的间充质干细胞的增殖、凋亡及细胞因子的影响[J]. 组织工程与重建外科杂志, 2019, 15(1): 5-9.
[10]	张俊, 姜毓, 沈柏用.胰腺神经内分泌肿瘤的治疗[J]. 外科理论与实践, 2019, 24(03): 208-211.
[11]	程燕咏，王佳怡，蒋云凤，孙宇.骨髓间充质干细胞对七氟烷所致的原代神经元凋亡及细胞活性的影响[J]. 组织工程与重建外科杂志, 2018, 14(1): 24-27.
[12]	朱红灿, 高萌, 张新凯,.急性一氧化碳中毒迟发性脑病发病机制的研究进展[J]. 内科理论与实践, 2018, 13(05): 264-268.
[13]	马韵芳, 潘丽娜, 张培培, 何清, 徐志红, 胡家安.人类表皮生长因子受体2基因扩增的非小细胞肺癌一例报告[J]. 诊断学理论与实践, 2018, 17(04): 462-465.
[14]	赵莉娟，郑江红，柳向东，茅广宇，邓辰亮，杨松林.iRGD-外泌体-阿霉素抑制恶性黑色素瘤体外增殖的研究[J]. 组织工程与重建外科杂志, 2017, 13(1): 25-28.
[15]	梁贇, 姜翀弋, 王巍,.胰腺癌的靶向治疗[J]. 外科理论与实践, 2017, 22(01): 84-88.